BB Biotech AG (LSE:0JYO) Cash And Cash Equivalents : €0.4 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is BB Biotech AG Cash And Cash Equivalents?

BB Biotech AG's quarterly cash and cash equivalents increased from Sep. 2023 (€0.34 Mil) to Dec. 2023 (€0.53 Mil) but then stayed the same from Dec. 2023 (€0.53 Mil) to Mar. 2024 (€0.42 Mil).

BB Biotech AG's annual cash and cash equivalents declined from Dec. 2021 (€2.72 Mil) to Dec. 2022 (€1.97 Mil) and declined from Dec. 2022 (€1.97 Mil) to Dec. 2023 (€0.53 Mil).

BB Biotech AG Cash And Cash Equivalents Historical Data

The historical data trend for BB Biotech AG's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Cash And Cash Equivalents Chart

BB Biotech AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

28.13

6.31

2.72

1.97

0.53

BB Biotech AG Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Dec17	Dec18	Dec19	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.77	0.92	0.34	0.53	0.42

BB Biotech AG Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BB Biotech AG (LSE:0JYO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BB Biotech AG Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BB Biotech AG (LSE:0JYO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (LSE:0JYO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BIONz:UK BBZA:Germany BION:Switzerland

Address

Schwertstrasse 6, Schaffhausen, CHE, CH-8200

Website

https://www.bbbiotech.com

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (LSE:0JYO) Headlines

No Headlines